• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Scinai Immunotherapeutics Ltd.

    10/1/25 5:32:54 PM ET
    $SCNI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $SCNI alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 5)


    Scinai Immunotherapeutics Ltd.

    (Name of Issuer)


    American Depositary Shares, each representing 4,000 Ordinary Shares, no par value

    (Title of Class of Securities)


    09073Q203

    (CUSIP Number)


    09/29/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    09073Q203


    1Names of Reporting Persons

    Stone Daniel E.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    346,667.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    346,667.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    346,667.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.9 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    CUSIP No.
    09073Q203


    1Names of Reporting Persons

    RK Stone Miami, LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    FLORIDA
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    282,467.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    282,467.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    282,467.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    8.1 %
    12Type of Reporting Person (See Instructions)

    CO

    Comment for Type of Reporting Person:  Based on 12,750,715,584 ordinary shares outstanding as of September 17, 2025, as disclosed by the issuer on September 22, 2025. Includes 64,200 American Depositary Shares (ADSs) held directly by the Reporting Person, 200,000 ADSs held by RK Stone Miami, LLC ("RK") and 82,467 ADSs issuable upon exercise of pre-funded warrants held by RK. On September 22, 2025, RK exercised 200,000 warrants. As of September 29, 2025, RK holds 200,000 ADSs and 283,426 ADS pre-funded warrants, which may not be exercised if such exercise would result in beneficial ownership by RK, together with its affiliates (which include the Reporting Person) and certain other persons, of greater than 9.99% of the ordinary shares. As disclosed in the Schedule 13G amendment filed with the Securities and Exchange Commission on January 24, 2025, future issuances of ordinary shares or ADSs by the issuer to third parties are expected to cause additional amounts of pre-funded warrants to become exercisable within the foregoing limitation, without increasing the reporting person's beneficial ownership percentage.


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Scinai Immunotherapeutics Ltd.
    (b)Address of issuer's principal executive offices:

    Jerusalem BioPark, 2nd Floor, Hadassah Ein Kerem Campus, Jerusalem, Israel, 0000000
    Item 2. 
    (a)Name of person filing:

    i) Daniel E. Stone ii) RK Stone Miami, LLC
    (b)Address or principal business office or, if none, residence:

    i) 1200 Brickell Avenue, #1470, Miami, FL 33131 ii) 1200 Brickell Avenue, #1470, Miami, FL 33131
    (c)Citizenship:

    i) United States ii) Florida
    (d)Title of class of securities:

    American Depositary Shares, each representing 4,000 Ordinary Shares, no par value
    (e)CUSIP No.:

    09073Q203
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    i) 346,667 ii) 282,467
    (b)Percent of class:

    i) 9.9 ii) 8.1
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    i) 346,667 ii) 282,467

     (ii) Shared power to vote or to direct the vote:

    0

     (iii) Sole power to dispose or to direct the disposition of:

    i) 346,667 ii) 282,467

     (iv) Shared power to dispose or to direct the disposition of:

    0

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Stone Daniel E.
     
    Signature:/s/ Daniel E. Stone
    Name/Title:Stone Daniel E.
    Date:10/01/2025
     
    RK Stone Miami, LLC
     
    Signature:/s/ Daniel E. Stone
    Name/Title:Sole Member - RK Stone Miami, LLC
    Date:10/01/2025
    Exhibit Information

    EXHIBIT 1.01 JOINT FILING AGREEMENT

    Get the next $SCNI alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SCNI

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $SCNI
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Scinai Immunotherapeutics Ltd.

    SCHEDULE 13G/A - Scinai Immunotherapeutics Ltd. (0001611747) (Subject)

    10/1/25 5:32:54 PM ET
    $SCNI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form EFFECT filed by Scinai Immunotherapeutics Ltd.

    EFFECT - Scinai Immunotherapeutics Ltd. (0001611747) (Filer)

    10/1/25 12:15:11 AM ET
    $SCNI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form F-1 filed by Scinai Immunotherapeutics Ltd.

    F-1 - Scinai Immunotherapeutics Ltd. (0001611747) (Filer)

    9/22/25 10:47:52 AM ET
    $SCNI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $SCNI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Scinai Reports Six-Month 2025 Financial Results Highlighting Continued CDMO Revenue Growth and Strengthened Balance Sheet

    JERUSALEM, Sept. 2, 2025 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI) ("Scinai", or the "Company"), a biopharmaceutical company focused on developing novel and innovative biological drug candidates for the treatment of inflammation and immunology (I&I) related diseases and on providing CDMO services through its Scinai Bioservices business unit, today announced its financial results for the six months ended June 30, 2025. Six-Month 2025 Financial Summary  Revenues for the six months ended June 30, 2025, totaled $773 thousand, compared to $284 thousand for the six months ended June 30, 2024. The increase reflects the continued growth of the Company's CDMO business, which gener

    9/2/25 7:30:00 AM ET
    $SCNI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Scinai Announces New Peer-Reviewed Publication Supporting PC111 as a Disease-Modifying Therapy for Pemphigus and SJS/TEN

    New data builds on award-winning research and confirms efficacy and safety of PC111 across in-vitro, ex-vivo, and in-vivo humanized models JERUSALEM, July 29, 2025 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI), a biopharmaceutical company developing inflammation and immunology (I&I) biological products and providing boutique CDMO services, announced the publication of a new peer-reviewed article in the Journal of Dermatological Treatment validating the disease-modifying potential of PC111, a first-in-class human anti-Fas Ligand monoclonal antibody. Authored by Dr. Roberta Lotti and colleagues from the University of Modena and Pincell Srl, the paper expands on Dr. Lotti's prio

    7/29/25 7:15:00 AM ET
    $SCNI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Scinai Highlights Award-Winning Science Behind PC111 as Key Pincell Researcher Receives "Oscar of Italian Dermatology"

    Dr. Roberta Lotti honoured for a pioneering work on PC111, reinforcing Scinai's strategic option agreement to acquire the Italian biotech company Pincell srl. JERUSALEM, June 26, 2025 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI), a biopharmaceutical company specializing in inflammation and immunology (I&I) biological products and in providing CDMO services through its Scinai Bioservices unit, proudly announces that Dr. Roberta Lotti, one of the lead scientists at Pincell Srl, has received the prestigious "Oscar of Italian Dermatology" from SIDeMaST, the Italian Society of Dermatology and Venereology. Dr. Lotti was recognized in the Immunopathology and Cutaneous Allergies cate

    6/26/25 7:37:00 AM ET
    $SCNI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $SCNI
    Leadership Updates

    Live Leadership Updates

    View All

    Scinai signs an option agreement to acquire rare disease company Pincell and its novel antibody for treating Severe Dermatological Conditions

    Scinai files an application for Euro 12 million grant to fund next stage of development Pincell's monoclonal antibody, PC111, is in development for treating Pemphigus, Steven Johnson's Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN)PC111 has already received an Orphan Drug Designation in Pemphigus by the European Medicine's AgencyAn application will be filed with the FDA for Orphan Drug and Breakthrough Designation in Pemphigus, as well as in SJS/TENScinai sees potential for accelerated approval given the severity of these diseases, PC111's innovative, non-immunosuppressive mode of action and the lack of effective alternative treatmentsJERUSALEM, March 27, 2025 /PRNewswire/ -- Scinai Imm

    3/27/25 9:25:00 AM ET
    $SCNI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Prof. Michael Schön, Director of Dermatology and Venereology at the University Medical Center Göttingen, Germany (UMG), Joins Scinai Immunotherapeutics' Scientific Advisory Board

    JERUSALEM, Dec. 5, 2024 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI) ("Scinai" or the "Company"), a biopharmaceutical company specializing in the development of inflammation and immunology (I&I) biological products and offering CDMO services through its Scinai Bioservices unit, announced today the appointment of Prof. Michael Schön to its Scientific Advisory Board (SAB). Prof. Michael Schön is a distinguished Professor and Director of the Department of Dermatology, Venereology, and Allergology at the University Medical Center Göttingen. He also serves as Vice D

    12/5/24 8:25:00 AM ET
    $SCNI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Scinai Welcomes Liat Halpert as Head of Business Development and Sales

    JERUSALEM, Feb. 13, 2024 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI), a biopharmaceutical company focused on developing inflammation and immunology (I&I) biological products and providing CDMO services through its Scinai Bioservices business unit, today announced the appointment of Liat Halpert as Head of Business Development and Sales. Halpert brings extensive pharmaceutical sales and marketing experience and joins Scinai following 14 years at Novartis, most recently having served as Marketing and Commercial Excellence Lead for cell and gene therapies for Central, Southern and Eastern Europe.     Scinai's broad pharmaceutical development experience, along with its end-to-e

    2/13/24 7:00:00 AM ET
    $SCNI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $SCNI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Scinai Immunotherapeutics Ltd.

    SC 13G/A - Scinai Immunotherapeutics Ltd. (0001611747) (Subject)

    11/14/24 4:28:57 PM ET
    $SCNI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Scinai Immunotherapeutics Ltd.

    SC 13G/A - Scinai Immunotherapeutics Ltd. (0001611747) (Subject)

    8/20/24 3:06:01 PM ET
    $SCNI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13D filed by Scinai Immunotherapeutics Ltd.

    SC 13D - Scinai Immunotherapeutics Ltd. (0001611747) (Subject)

    3/12/24 4:17:13 PM ET
    $SCNI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $SCNI
    Financials

    Live finance-specific insights

    View All

    Scinai Reports Six-Month 2025 Financial Results Highlighting Continued CDMO Revenue Growth and Strengthened Balance Sheet

    JERUSALEM, Sept. 2, 2025 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI) ("Scinai", or the "Company"), a biopharmaceutical company focused on developing novel and innovative biological drug candidates for the treatment of inflammation and immunology (I&I) related diseases and on providing CDMO services through its Scinai Bioservices business unit, today announced its financial results for the six months ended June 30, 2025. Six-Month 2025 Financial Summary  Revenues for the six months ended June 30, 2025, totaled $773 thousand, compared to $284 thousand for the six months ended June 30, 2024. The increase reflects the continued growth of the Company's CDMO business, which gener

    9/2/25 7:30:00 AM ET
    $SCNI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Scinai Reports Q1 2025 Financial Results Highlighting Strong CDMO Revenue Momentum and Reduced Cash Burn

    JERUSALEM, May 30th, 2025 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI) ("Scinai", or the "Company"), a biopharmaceutical company focused on developing novel and innovative biological drug candidates for the treatment of inflammation and immunology (I&I) related diseases and on providing CDMO services through its Scinai Bioservices business unit, today announced its financial results for the first three months ended March 31, 2025. Three (3) Months of 2025 Financial Summary Revenues for the three months ended March 31, 2025, totaled $586 thousand. The Company's CDMO unit began generating revenues in the second quarter ended June 30, 2024. As disclosed in the Company's Annual

    5/30/25 7:00:00 AM ET
    $SCNI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Scinai Publishes Financial Results and Provides Business Update; Shareholders' Equity up from negative $7.3 million as of June 30, 2024, to positive $10 million

    JERUSALEM, Nov. 22, 2024 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI) ("Scinai", or the "Company"), a biopharmaceutical company focused on developing inflammation and immunology (I&I) biological products and on providing CDMO services through its Scinai Bioservices business unit, today published its financial results for the nine months ended September 30, 2024 and provided a business update. Business Update & Recent Highlights Conversion of EIB Loan into Equity bringing shareholders' equity to $10 million On August 21, 2024, the Company announced that it had closed a Loan Restructuring Agreement, which included an amendment and restatement to the amended Finance Contract wi

    11/22/24 7:15:00 AM ET
    $SCNI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care